Last reviewed · How we verify
RBV(48 weeks)
Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis.
Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis. Used for Chronic hepatitis C, Hepatitis C in combination with other medications.
At a glance
| Generic name | RBV(48 weeks) |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Nucleoside analog |
| Target | RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the viral RNA polymerase, preventing the replication of the virus. This leads to a decrease in viral load and an improvement in symptoms.
Approved indications
- Chronic hepatitis C
- Hepatitis C in combination with other medications
Common side effects
- Anemia
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
- Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy
- Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy (PHASE4)
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (EARLY_PHASE1)
- Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB (NA)
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (PHASE2)
- Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBV(48 weeks) CI brief — competitive landscape report
- RBV(48 weeks) updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI